Nicotine Dependence
Conditions
Keywords
Tobacco, Smoking, TMS, fMRI, Nicotine, Cognitive Control
Brief summary
The purpose of the study is to examine the effects of continuous theta burst stimulation (cTBS) on different forms of cognitive control in adults who smoke cigarettes, and to determine if the location where cTBS is delivered may help smokers reduce or quit smoking. Participation in the study will take 3-weeks over 4 visits, with a total time commitment of approximately 12 hours.
Interventions
DEVICERepetitive Transcranial Magnetic Stimulation (rTMS)
Continuous theta burst rTMS
Sponsors
University of Missouri-Columbia
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Nicotine Dependence as measured by: Smoke ≥ 8 cigarettes/day for ≥ 2 yrs, expired carbon monoxide (CO) concentration of ≥ 10 ppm, positive urine cotinine test and FTND score ≥ 3 Or ≥ 15 uses of electronic cigarette/day for ≥ 1 year, positive urine cotinine test, and PS-ECDI score ≥ 3 2. English Fluency 3. Functional Vision (with corrective lenses as needed)
Exclusion criteria
1. Use of psychotropic and antiepileptic medications in the last month 2. Presence of an untreated illness or serious medical condition 3. History of major neurological illness 4. Contraindication to TMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \>15 min., implanted electronic device, metal in the head) or MRI. 5. Any use of substances that lower seizure threshold. 6. Current or past psychosis 7. Electroconvulsive therapy in the past 6 months 8. Unstable cardiac disease or hypertension, severe renal or liver insufficiency, or sleep apnea 9. BAC greater than 0.0. 10. Positive urine pregnancy test 11. Any other concern that in the investigator's opinion would impact participant safety, study instruction compliance, or confound the interpretation of the study results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute effects of cTBS on cognitive control | 1 hour after receiving cTBS | between-arm differences in neurocognitive task performance as measured by percent correct on an inhibitory control task and self reported craving on a regulation of craving task. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exploratory: Acute effects of cTBS on fMRI brain response | 1 hour after receiving cTBS | between-arm differences in whole brain fMRI BOLD functional connectivity. Neural network connectivity will be characterized using rZ values. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability | 24 hours following receipt of cTBS | Safety and tolerability of cTBS administered to each cortical location, as measured by self reported side effects on a review of symptoms questionnaire. |
Countries
United States
Contacts
Primary ContactBrett Froeliger, PhD
Outcome results
None listed